MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria and Sanaria’s CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
In the December, 2008 issue of Esquire, read the great discussion of malaria and the critical, innovative work that Sanaria is doing to develop new vaccines.
Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites
Every day 2000 children die from malaria in Africa alone. The infec6on is transmi9ed from human to human by bi6ng mosquitoes and remains one of the world’s most devasta6ng diseases. Despite many years of effort a vaccine is s6ll not available but is urgently needed, if we are to make an impact on this enormous problem.
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Malaria vaccine developer Sanaria Inc. receives the Technology Council of Maryland’s Emerging Company of the Year Award.
Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland’s Tech Awards Celebration honoring the state’s technology leaders and organizations.
Self-Experimenters: Malaria Vaccine Maven Baits Irradiated Mosquitoes with His Own Arm
Stephen Hoffman has given years of sweat—and lots of blood—on his quest to stop a global killer. Read the full article in Scientific American.
Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
Today Top Institute Pharma announces a highly promising research project that is aimed at the development of a malaria vaccine. This TI Pharma project will be an expansion of extremely promising findings from previous studies.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.